CLNN Stock Summary and Trading Ideas (Clene | NASDAQ:CLNN)

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

Clene trades on the NASDAQ stock market under the symbol CLNN.

As of January 30, 2026, CLNN stock price declined to $4.09 with 61,806 million shares trading.

CLNN has a beta of 2.12, meaning it tends to be more sensitive to market movements. CLNN has a correlation of 0.07 to the broad based SPY ETF.

CLNN has a market cap of $48.17 million. This is considered a Sub-Micro Cap stock.

Last quarter Clene reported $15,000 in Revenue and -$.85 earnings per share. This fell short of revenue expectation by $-50,084 and missed earnings estimates by -$.27.

In the last 3 years, CLNN traded as high as $39.80 and as low as $2.28.

The top ETF exchange traded funds that CLNN belongs to (by Net Assets): VTI, VXF.

CLNN has underperformed the market in the last year with a price return of -13.9% while the SPY ETF gained +15.6%. CLNN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -59.1% and -19.0%, respectively, while the SPY returned +2.1% and 0.0%, respectively.

CLNN support price is $3.83 and resistance is $4.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLNN shares will trade within this expected range on the day.